Gyre Therapeutics, Inc. (GYRE) Stock Grade

About Gyre Therapeutics, Inc.'s fundamentals

Gyre Therapeutics is a biotechnology company with a market capitalization of $835.1 million, currently trading at a P/E ratio of 125.5, which is significantly elevated relative to its earnings. The company generated revenue growth of 10.2% year-over-year, though profitability remains modest with a net margin of 4.3% and a return on equity of just 4.7%, indicating limited earnings relative to shareholder capital. Gyre does not pay a dividend, suggesting the company is reinvesting cash into operations or research rather than distributing returns to shareholders.